Skybiotech Healthcare Ltd (512036)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Skybiotech Healthcare's revenue was ₹0.5 Cr (-79.4% year on year, -73.1% on the previous quarter), and net profit ₹-0.6 Cr (a bigger loss than a year earlier); the operating margin was -106.4%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.5 | -79.4% | -73.1% |
| Operating profit | ₹-0.5 | to loss | loss narrowed |
| Net profit | ₹-0.6 | loss widened | loss widened |
| EPS (₹) | -2.56 | loss widened | loss widened |
| Operating margin | -106.4% | — | — |
📢 Recent Corporate Announcements
Skybiotech Healthcare Limited (formerly Kapil Cotex Ltd) announced that its Board of Directors approved the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The board meeting was conducted on August 14, 2026, between 05:00 PM and 08:45 PM, and the statutory auditors' Limited Review Report was taken on record. The filing extract serves as the official meeting outcome intimation without attached detailed income statement line items.
- Board approved Un-Audited Standalone and Consolidated Financial Results for quarter ended June 30, 2026
- Limited Review Report from Statutory Auditors formally taken on record
- Board meeting commenced at 05:00 PM and concluded at 08:45 PM on August 14, 2026
Skybiotech Healthcare Limited approved its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, at its board meeting on August 14, 2026. For the quarter, the company posted a revenue of ₹0.49 crore alongside an operating loss of ₹0.52 crore. Net loss for the period stood at ₹0.57 crore with a basic EPS of -₹2.56. The statutory auditor's limited review report was also taken on record without explicit modifications mentioned in the outcome filing.
- Board approved Un-Audited Financial Results for the quarter ended June 30, 2026 on August 14, 2026
- Reported quarterly revenue of ₹0.4931 crore for the period
- Recorded an operating loss of ₹0.5246 crore and net loss of ₹0.5736 crore (EPS of -₹2.56)
- Board meeting commenced at 05:00 PM and concluded at 08:45 PM on August 14, 2026
Skybiotech Healthcare Ltd (formerly Kapil Cotex Ltd) has scheduled a board meeting for August 14, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of Rs 32 crore and has reported zero revenue for the last four consecutive quarters. With a TTM EPS of Rs -0.26 and a net worth of Rs 12 crore, the upcoming results will be monitored for any signs of operational commencement. This is a routine regulatory filing under SEBI (LODR) Regulations.
- Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results.
- Company reported Rs 0.0 crore revenue in each of the last four quarters ending March 2026.
- Market capitalization is currently Rs 32 crore against a net worth of Rs 12 crore.
- TTM EPS stands at Rs -0.26, reflecting lack of operational profitability.
- Promoter holding has remained stable at 63.48% as of March 2026.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
